Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Advances in Myeloma Precursor Conditions in the 21st Century

The inaugural meeting on Advances in Myeloma Precursor Conditions in the 21st Century organized by the Multiple Myeloma Research Foundation and the Dana-Farber Cancer Insitute took place on the 20th of August and highlighted recent advances in the management of MGUS, smoldering myeloma and multiple myeloma, as well as looking to the next five years.

The full series of presentations can be viewed on-demand below.

Session I: Clinical Aspects
  • History of MGUS and SMM and prognostic markers: Rafael Fonseca
Session I
Session II: Genomics of SMM
  • Genomic markers using WGS: Niccolò Bolli
  • Genomic Markers using WES: Mark Bustoros & Romanos Sklavenitis Pistofidis
  • Molecular timing of initiationOla Landgren & Francesco Maura
Session II
Session III: Immune Microenvironment of SMM
  • Single-cell RNA sequencing of SMM: Gad Getz & Nicholas Haradhvala
  • Immune profiling in MGUS and SMM: Bruno Paiva
Session III
Session IV: Trials and Endpoints
  • Innovative endpoints for MM trials: Nicole Gormley
  • Phase III trials of SMM: Sagar Lonial
  • Antibodies: Elisabet Manasanch
  • Current ongoing studies of a potential cure for SMM: Shaji Kumar
  • Ongoing studies of 3 drug combinations: Omar Nadeem
Session IV

irene ghobrial, maria victoria mateos, Saad Usmani

Our Multiple Myeloma Channel examines the latest updates across the myeloma field.

With content featuring expert interviews from major international congresses, this is one for your bookmarks!

To keep updated on all the latest in myeloma and beyond, subscribe to our newsletter here.